Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
procarbazine + lomustine + vincristine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Procarbazine + lomustine + vincristine (commonly referred to as "PCV") is a combination chemotherapy regimen used primarily in the treatment of certain brain tumors, especially gliomas and anaplastic oligodendroglial tumors. Each component has a distinct mechanism of action: - Procarbazine is an alkylating agent that inhibits DNA, RNA, and protein synthesis by causing DNA strand breaks. - Lomustine (also known as CCNU) is a nitrosourea alkylating agent that cross-links DNA and RNA. - Vincristine is a vinca alkaloid that inhibits microtubule formation in mitotic spindle fibers during cell division. Together, these drugs target rapidly dividing cancer cells through complementary mechanisms. The regimen has been shown to improve overall survival when combined with radiation therapy for certain gliomas[1][5]. Administration involves oral capsules for procarbazine and lomustine and intravenous infusion for vincristine[1][2].
- Brand names
- MatulaneNatulanIndicarbGleostineCeeNUCuuNuOncovin
- Other names
- PCVprocarbazinelomustinevincristine
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on procarbazine + lomustine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on procarbazine + lomustine + vincristine.